Olaf Prien

457 total citations
16 papers, 353 citations indexed

About

Olaf Prien is a scholar working on Pulmonary and Respiratory Medicine, Organic Chemistry and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Olaf Prien has authored 16 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Organic Chemistry and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Olaf Prien's work include Prostate Cancer Treatment and Research (6 papers), Chemical Synthesis and Analysis (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Olaf Prien is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Chemical Synthesis and Analysis (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Olaf Prien collaborates with scholars based in Germany, Finland and United Kingdom. Olaf Prien's co-authors include Christian Zurth, Mikko Koskinen, Robert E. Fricke, Hille Gieschen, Timo Korjamo, Karsten Denner, Martina Schäfer, Gary Wilkinson, Gerhard Siemeister and Hans Briem and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry and Annals of Oncology.

In The Last Decade

Olaf Prien

16 papers receiving 337 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olaf Prien Germany 10 141 126 98 68 56 16 353
Aakanksha Khandelwal United States 11 127 0.9× 62 0.5× 276 2.8× 26 0.4× 81 1.4× 14 488
Gary Wilkinson United Kingdom 10 78 0.6× 125 1.0× 327 3.3× 28 0.4× 179 3.2× 23 546
Hille Gieschen Germany 12 219 1.6× 27 0.2× 90 0.9× 101 1.5× 105 1.9× 16 455
Tetsuo Asaki Japan 11 162 1.1× 136 1.1× 163 1.7× 15 0.2× 81 1.4× 14 658
Clémentine Féau United States 9 152 1.1× 77 0.6× 235 2.4× 18 0.3× 54 1.0× 13 469
A. Thomas DiCioccio United States 12 29 0.2× 142 1.1× 129 1.3× 58 0.9× 74 1.3× 22 551
Andrew K. Kwegyir‐Afful United States 10 186 1.3× 38 0.3× 247 2.5× 20 0.3× 51 0.9× 12 392
Lenka Goldman United States 13 82 0.6× 60 0.5× 325 3.3× 51 0.8× 88 1.6× 22 571
Alicja Puszkiel France 10 50 0.4× 30 0.2× 106 1.1× 27 0.4× 134 2.4× 29 304
Olli Törmäkangas Finland 6 250 1.8× 58 0.5× 104 1.1× 73 1.1× 52 0.9× 9 355

Countries citing papers authored by Olaf Prien

Since Specialization
Citations

This map shows the geographic impact of Olaf Prien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olaf Prien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olaf Prien more than expected).

Fields of papers citing papers by Olaf Prien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olaf Prien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olaf Prien. The network helps show where Olaf Prien may publish in the future.

Co-authorship network of co-authors of Olaf Prien

This figure shows the co-authorship network connecting the top 25 collaborators of Olaf Prien. A scholar is included among the top collaborators of Olaf Prien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olaf Prien. Olaf Prien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Taavitsainen, Päivi, Olaf Prien, Michael Niehues, et al.. (2021). Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans. Drug Metabolism and Disposition. 49(6). 420–433. 9 indexed citations
2.
3.
Taavitsainen, Päivi, Hille Gieschen, Timo Korjamo, et al.. (2020). Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats. Xenobiotica. 50(8). 967–979. 9 indexed citations
4.
Zurth, Christian, Mikko Koskinen, Robert E. Fricke, et al.. (2019). Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. European Journal of Drug Metabolism and Pharmacokinetics. 44(6). 747–759. 71 indexed citations
5.
6.
Zurth, Christian, Karim Fizazi, Robert E. Fricke, et al.. (2019). Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO). Annals of Oncology. 30. v350–v350. 3 indexed citations
7.
Zurth, Christian, Karsten Denner, Timo Korjamo, et al.. (2019). Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies.. Journal of Clinical Oncology. 37(7_suppl). 297–297. 9 indexed citations
8.
Höchel, Joachim, Olaf Prien, Torsten Zimmermann, et al.. (2018). Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug–Drug Interaction Potential. Clinical Pharmacokinetics. 57(8). 1001–1015. 25 indexed citations
9.
Milburn, Robert R., Syed Muhammad Shakil Hussain, Olaf Prien, Zaheer Ahmed, & Victor Snieckus. (2007). 3,3‘-Dipyridyl BINOL Ligands. Synthesis and Application in Enantioselective Addition of Et2Zn to Aldehydes. Organic Letters. 9(22). 4403–4406. 25 indexed citations
10.
Prien, Olaf. (2006). The Gatekeeper: Friend or Foe in Identifying the Next Generation of Kinase Inhibitors. ChemMedChem. 1(11). 1195–1196. 5 indexed citations
11.
12.
Jautelat, Rolf, Thomas Brumby, Martina Schäfer, et al.. (2005). From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors. ChemBioChem. 6(3). 531–540. 71 indexed citations
13.
14.
15.
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aakanksha Khandelwal Breakdown of academic impact, for papers by Gary Wilkinson Breakdown of academic impact, for papers by Hille Gieschen Breakdown of academic impact, for papers by Tetsuo Asaki Breakdown of academic impact, for papers by Clémentine Féau Breakdown of academic impact, for papers by A. Thomas DiCioccio Breakdown of academic impact, for papers by Andrew K. Kwegyir‐Afful Breakdown of academic impact, for papers by Lenka Goldman Breakdown of academic impact, for papers by Alicja Puszkiel Breakdown of academic impact, for papers by Olli Törmäkangas
Rankless by CCL
2026